Longevity Biotech Companies GERO And FOXO Technologies To Embark On Joint Initiative On Artificial Intelligence And Epigenetic Data To Discover Signatures Of Human Health Trajectories
Portfolio Pulse from Benzinga Newsdesk
AI-driven biotechnology company GERO and epigenetic biomarker discovery leader FOXO Technologies Inc. (NYSEAM:FOXO) have begun discussions to form a strategic collaboration. The partnership aims to develop an AI-driven personalized wellness and longevity recommendation engine based on proprietary epigenetic data.
August 07, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
FOXO Technologies is in discussions with GERO for a strategic collaboration to develop an AI-driven wellness and longevity recommendation engine.
The potential collaboration with GERO could lead to the development of a new product, which could increase FOXO's market share and revenues. This is likely to have a positive impact on FOXO's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100